Evidence-Based Summary
Ghrelin is a 28-amino-acid endogenous peptide hormone primarily secreted by enteroendocrine P/D1 cells in the gastric fundus. It is uniquely modified by the enzyme ghrelin O-acyltransferase (GOAT) with an n-octanoyl fatty acid group at serine-3, a post-translational modification essential for crossing the blood-brain barrier and binding to the Growth Hormone Secretagogue Receptor 1a (GHSR-1a). Native ghrelin acts as the body's primary peripheral orexigenic signal: it stimulates intense hunger via hypothalamic NPY/AgRP neurons, while simultaneously acting on anterior pituitary somatotrophs to stimulate growth hormone release, ACTH/cortisol secretion, and prolactin release. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered specifically to decouple these physiological actions. By acting as a selective agonist at GHSR-1a, ipamorelin triggers episodic GH secretion from somatotrophs through intracellular calcium mobilization, but shows selectivity: in animal and early human trials, it provoked virtually no release of ACTH, cortisol, or prolactin, and did not stimulate the intense pre-meal hunger surges characteristic of native ghrelin. Neither peptide is approved by the FDA for therapeutic endocrine optimization; ghrelin is studied in clinical trials for cancer cachexia, while ipamorelin remains an unapproved research compound prohibited by WADA under Section S2.
Quick Comparison: Ipamorelin vs Ghrelin
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Ipamorelin | Ghrelin |
|---|---|---|
| Biological classification | Synthetic selective GH secretagogue | Endogenous acylated gastrointestinal hormone |
| Receptor target | GHSR-1a (Selective pituitary activation) | GHSR-1a (Broad hypothalamic, pituitary, and enteric) |
| Peptide structure | 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) | 28 amino acids (with n-octanoyl group at Ser3) |
| Post-translational acylation | None required (Active as synthesized) | Essential n-octanoylation via GOAT enzyme |
| Appetite stimulation | Negligible to mild in preclinical models | Potent orexigenic trigger (Primary physiological hunger signal) |
| ACTH & Cortisol release | Spared (Does not elevate cortisol in trials) | Significantly stimulates ACTH and cortisol release |
| Prolactin release | Spared (Does not elevate prolactin) | Stimulates prolactin secretion |
| WADA status | Prohibited at all times (Section S2) | Prohibited at all times (Section S2: Ghrelin & secretagogues) |
Decoupling Growth Hormone Release from Appetite & Stress Axes
How medicinal chemists designed ipamorelin to achieve biased somatotroph selectivity at GHSR-1a.
Ipamorelin: Selective Pituitary Somatotroph Agonism
Primary Target: GHSR-1a (Growth Hormone Secretagogue Receptor 1a)
Affinity Profile: High selectivity for GHSR-1a; EC50 ~1.3 nM
Ipamorelin binds GHSR-1a on somatotrophs, activating Gαq and phospholipase C to trigger inositol triphosphate (IP3)-mediated calcium mobilization. It was deliberately engineered with unnatural D-amino acids to avoid activation of hypothalamic NPY/AgRP hunger centers or corticotroph ACTH release, producing clean GH secretagogue action.
Ghrelin: Systemic Neuroendocrine & Orexigenic Cascade
Primary Targets: GHSR-1a (Central and peripheral receptors)
Affinity Profile: Sub-nanomolar affinity; requires octanoyl group at Ser3
Active acyl-ghrelin crosses the blood-brain barrier and activates GHSR-1a on hypothalamic arcuate NPY/AgRP neurons, stimulating food-seeking behavior and adipogenesis. Simultaneously, ghrelin acts on pituitary somatotrophs to release GH and on corticotrophs to stimulate ACTH and cortisol as part of the adaptive fasting response.
Experimental Status & Investigational Oncology Trials
Neither substance has achieved marketing authorization for general medical use.
Ipamorelin Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Ghrelin Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Ghrelin receptor agonists (such as anamorelin) have been evaluated in Phase 3 clinical trials for cancer-related anorexia-cachexia syndrome in lung cancer. Ipamorelin remains an unapproved research compound.
Human Pharmacology Infusion Studies
Clinical research comparing the endocrine output of ghrelin and synthetic secretagogues.
Ipamorelin: Ipamorelin Clinical Trials
In early Phase 1 human trials (Gobburu et al., 1999), ipamorelin produced sharp, dose-dependent increases in plasma GH within 40 minutes, while plasma ACTH, cortisol, and prolactin levels remained unchanged compared to placebo.
Ghrelin: Ghrelin Clinical Research
Human infusion studies by Wren et al. (Diabetes 2001; J Clin Endocrinol Metab 2001) demonstrated that acute intravenous infusion of native ghrelin increased acute energy intake by 28% while concurrently tripling circulating GH, ACTH, and cortisol.
Comparative Endocrine Side Effects
The primary clinical difference lies in the avoidance of cortisol elevation and appetite stimulation.
| Safety Consideration | Ipamorelin | Ghrelin |
|---|---|---|
| Appetite stimulation | Negligible | Severe, immediate hunger urges |
| Cortisol & stress axis | Spared; does not activate HPA axis | Acute elevation of plasma ACTH and cortisol |
| Prolactin elevation | Spared | Dose-dependent prolactin surges |
What Ipamorelin and Ghrelin Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
GHSR-1a Binding
Both peptides bind the exact same growth hormone secretagogue receptor 1a.
Pituitary GH Release
Both trigger rapid intracellular calcium mobilization to release growth hormone.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Orexigenic Hunger
Ghrelin is the primary natural hunger hormone; ipamorelin does not induce severe hunger.
HPA Axis Activation
Ghrelin elevates ACTH and cortisol; ipamorelin spares the corticotroph axis.
Chemical Structure
Ghrelin is a 28-AA acylated peptide; ipamorelin is a synthetic 5-AA unnatural peptide.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Ipamorelin is just artificial ghrelin that will make you ravenously hungry
insufficientScientific misunderstanding of receptor selectivity.
Ipamorelin was specifically designed by medicinal chemists to avoid stimulating hypothalamic hunger centers. It provides selective pituitary GH secretagogue action without the orexigenic surge of native ghrelin.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Selective GH Secretion
Ipamorelin proven to stimulate GH while sparing cortisol/prolactin in early human studies.
Appetite Stimulation
Ghrelin is a validated orexigenic peptide; ipamorelin does not trigger significant hunger.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Long-Term GHSR Agonism and Insulin Sensitivity
Evaluating whether chronic GHSR-1a stimulation impairs peripheral insulin sensitivity over months of continuous use.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed Article
Ghrelin induces food intake in humans
-
Peer-Reviewed Article
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteers